Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$423.65 USD

423.65
553,842

-6.17 (-1.44%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $423.84 +0.19 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?

by Zacks Equity Research

Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year.

Should You Invest in the First Trust Water ETF (FIW)?

by Zacks Equity Research

Sector ETF report for FIW

TMO vs. IDXX: Which Stock Is the Better Value Option?

by Zacks Equity Research

TMO vs. IDXX: Which Stock Is the Better Value Option?

Molina Healthcare (MOH) Q4 Earnings Beat on Solid Medicaid Unit

by Zacks Equity Research

Molina Healthcare's (MOH) fourth-quarter results benefit from its strong Medicaid and Medicare businesses. Management expects 2023 adjusted EPS at a minimum of $19.75.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases

by Zacks Equity Research

IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 6.77% and 1.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.

Here's How Much a $1000 Investment in Idexx Laboratories Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?

by Zacks Equity Research

Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.

The Zacks Analyst Blog Highlights Expedia, IDEXX Laboratories, Tradeweb Markets, SolarEdge Technologies and Sanofi

by Zacks Equity Research

Expedia, IDEXX Laboratories, Tradeweb Markets, SolarEdge Technologies and Sanofi are included in this Analyst Blog.

SONVY or IDXX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SONVY vs. IDXX: Which Stock Is the Better Value Option?

Nalak Das headshot

Top 5 Nasdaq Composite Stocks to Buy Ahead of Q4 Earnings

by Nalak Das

Five Nasdaq Composite companies are set to beat earnings estimates. These are: EXPE, IDXX, SNY, TW and SEDG.

HCA Healthcare (HCA) Q4 Earnings Lag on High Costs, Hikes Dividend

by Zacks Equity Research

HCA Healthcare's (HCA) fourth-quarter results suffer a blow from added expenses incurred due to Hurricane Ian. Increased patient admissions partly offset the downside.

Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

by Zacks Equity Research

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q4 owing to continued rise in Catalyst and premium hematology placements.

Why You Should Hold Molina Healthcare (MOH) in Your Portfolio

by Zacks Equity Research

Molina Healthcare (MOH) remains well-poised for growth on the back of a growing customer base within its Government business. Acquisitions and cost-saving measures also aid the health insurer.

Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Why Idexx (IDXX) Could Beat Earnings Estimates Again

by Zacks Equity Research

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement

by Zacks Equity Research

IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.

Sweta Killa headshot

5 Stocks Powering Nasdaq ETF to Start 2023

by Sweta Killa

The rally has been broad-based. And the high beta and high growth sector took charge, with the tech-heavy Nasdaq Composite Index rising 5.1% in the initial two weeks of 2023.

Here's Why You Should Invest in IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) owing to strong international growth.